1. Home
  2. GGB vs COGT Comparison

GGB vs COGT Comparison

Compare GGB & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gerdau S.A.

GGB

Gerdau S.A.

HOLD

Current Price

$4.15

Market Cap

7.1B

Sector

Industrials

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$39.17

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGB
COGT
Founded
1901
2014
Country
Brazil
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
6.5B
IPO Year
1999
2018

Fundamental Metrics

Financial Performance
Metric
GGB
COGT
Price
$4.15
$39.17
Analyst Decision
Strong Buy
Buy
Analyst Count
1
13
Target Price
$4.60
$30.17
AVG Volume (30 Days)
11.3M
2.4M
Earning Date
02-23-2026
02-24-2026
Dividend Yield
2.45%
N/A
EPS Growth
N/A
N/A
EPS
0.28
N/A
Revenue
$13,079,666,170.00
N/A
Revenue This Year
$6.59
N/A
Revenue Next Year
$2.59
N/A
P/E Ratio
$13.65
N/A
Revenue Growth
7.37
N/A
52 Week Low
$2.27
$3.72
52 Week High
$4.20
$43.73

Technical Indicators

Market Signals
Indicator
GGB
COGT
Relative Strength Index (RSI) 70.79 60.74
Support Level $3.68 $33.84
Resistance Level $4.20 $36.88
Average True Range (ATR) 0.09 1.93
MACD 0.03 0.07
Stochastic Oscillator 90.00 75.53

Price Performance

Historical Comparison
GGB
COGT

About GGB Gerdau S.A.

Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutors, mechanical construction bars, and reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives the majority of its revenue from the Brazil Operations segment.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: